Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations — Stella

View on ClinicalTrials.gov

Recruiting

Back to GATA2 trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

National Institutes of Health Clinical Center, Bethesda, Maryland

Key details

Phase

Safety & dosing

Sponsor

National Cancer Institute (NCI)

Enrollment target

~144 participants

Started

July 2013

Primary completion

December 2027

Age range

6 Years – 70 Years

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.